Business Wire

Total Economic ImpactTM Study Finds Degreed Can Deliver 312% ROI and 35% Improved Upskilling Efficiency for Employees Over Three Years

15.6.2022 15:04:00 EEST | Business Wire | Press release

Share

Degreed, a pioneer in learning experience for eight million users, today shared the results of a commissioned Total Economic ImpactTM (TEI) study of its Learning Experience Platform (LXP). The study, conducted by Forrester Consulting found that organizations using Degreed’s LXP experienced faster time-to-productivity for new employees, democratization of learning across the workforce, improved upskilling, and lower learning content costs. The potential total return-on-investment calculated in the study was 312%, with a net present value (NPV) of $4.69M and payback in under six months. Read the full study here.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615005110/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The study found that Degreed delivers 312% ROI. (Graphic: Business Wire)

“Our customers choose Degreed alongside their LMSs and HCM systems to build the skills their people need faster and more efficiently. We believe this Total Economic ImpactTM study highlights how Degreed’s more open, collaborative learning experience can create value at every stage of the employee lifecycle — from faster new hire onboarding to more efficient upskilling and lower turnover in key roles, not to mention reduced content spend and higher productivity for L&D teams,” said Todd Tauber, SVP Strategy at Degreed.

The study found organizations using Degreed had a 20% faster time-to-productivity for new employees due to a more consistent onboarding process, centered around high quality content and easily navigated learning pathways.

According to the study, “Interviewees’ organizations used Degreed to upskill employees and improve their organizations’ performance in a number of areas, including customer satisfaction and retention, data storage and analysis, product support, diversity and inclusion, leadership and management, and technology changes.”

One professional services organization was able to make onboarding more relevant and timely for new starters, where previously it depended on live instructors at synchronous training sessions, which delayed onboarding timelines and made the experience inconsistent.

Another customer commented on the benefits of the LXP’s open ecosystem, stating, “Degreed is the primary learning interface for us and it caters to the diverse needs of our employees, as well as our organization. With Degreed, we've achieved targeted and business-focused skill development.”

The improved upskilling of current employees across all respondents was 35% for employees and 25% for trainers because of the single gateway for all learning that Degreed provides. The study additionally found that Degreed led to better retention in key roles, decreasing from 10% to 2%, particularly in leadership positions and those who regularly deal with new challenges.

There were additional unquantified benefits that were identified by the study including bringing a social, consumer-grade learning experience to corporate learning, leading to higher levels of engagement, and the democratization of learning, particularly for frontline workers, those in new regions, and employees speaking different languages.

Interviewees also said that Degreed was one of their organization’s core technologies that provided the agility needed to successfully operate through remote work.

To read the full study, click here.

Degreed is hosting a webinar featuring Forrester to dive further into the details of the study, click here to register.

Editor’s notes

TEI Framework And Methodology

From the information provided in the interviews, Forrester constructed a Total Economic ImpactTM framework for those organizations considering an investment in Degreed.

The objective of the framework is to identify the cost, benefit, flexibility, and risk factors that affect the investment decision. Forrester took a multistep approach to evaluate the impact that Degreed can have on an organization.

About Degreed

Degreed empowers growth and innovation through lifelong learning. As a changemaker on a global scale, we serve more than 100 of the Global 2000 and one in three Fortune 50 companies, sparking a culture of learning across the enterprise. In one fluid experience, we help you identify the skills you have and build the skills you need—through individual, collaborative and experiential modes of learning—to drive personal career growth and business results. Founded in 2012, Degreed is translated into 28 languages with users spanning more than 200 countries.

Learn more about Degreed: Website | YouTube | LinkedIn | Twitter

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lori Stafford-Thomas
Vice President Corp. Marketing, Degreed
lstafford-thomas@degreed.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye